Medline Stock Soars 12%, Adding $3.6 Billion, After Raising Sales Outlook And Authorizing Buyback

The medical supplier lifted its organic sales growth forecast and approved a $1 billion repurchase alongside third-quarter results.

Share
Medline Stock Soars 12%, Adding $3.6 Billion, After Raising Sales Outlook And Authorizing Buyback

Medline, which makes and distributes medical-surgical supplies for hospitals and other care sites, saw its shares climb 12.03% to $38.19 in Wednesday trading, as of 9:59 a.m. ET, adding $3.6 billion in market value. The company raised its full-year organic sales growth forecast and its board approved a $1 billion buyback alongside third-quarter results.

Sales up, profit slightly down

Sales grew 10.4% to $7.9 billion, per the filing, but profit was $318 million, down 1.2%.

Adjusted EBITDA, an adjusted earnings measure, reached $960 million, up 11.8%. Tariff refunds contributed $81 million to the quarter.

Medline now expects organic sales growth of 10.0% to 10.5% for the year, up from a prior range of 9.0% to 10.0%. It held its annual adjusted EBITDA range of $3.3 billion to $3.4 billion.

Fire loss and tariff refunds

For the first nine months, profit fell 28.8% to $696 million. A $316 million loss from a fire at its Tracy, California, facility helps explain the drop.

Nine-month refunds totaled $324 million.

A stock down 19% this year

Medline sells its own-brand products, such as wound care, exam gloves and surgical procedure trays, and distributes other suppliers' goods, with many customers on multi-year Prime Vendor agreements. It offers about 335,000 products across 70 distribution and related facilities and 30 manufacturing facilities, according to its annual report.

The stock was down about 19% year to date at Tuesday's close, while the S&P 500 was up about 11%. Wednesday's move put it on pace for a fourth straight daily gain and its biggest one-day gain in at least 220 trading sessions, since Dec. 18, 2025.

The company's market value stood at $33.5 billion in Wednesday morning trading.

Sources

More on Medline

All Medline (MDLN) coverage →